Roche has responded to our request by answering questions from the community regarding their recent decision to not initiate any new trials of rugonersen (RO7248824) in Angelman syndrome.
Questions & Answers from Roche
Please consider joining the ASF/FAST hosted webinar on July 7 at 12pm ET with Dr. Elizabeth Berry-Kravis, a principal investigator for the Roche (Tangelo) program.